Les maladies lysosomales sont des maladies génétiques dues au défaut du catabolisme de certaines molécules complexes au sein du lysosome. Les progrès. Morocco. Association Espoir Vaincre les Maladies Lysosomales au Maroc City: RABAT Phone: + L’association Espoir VML Maroc a été créée. Les maladies lysosomales (ML) constituent un groupe hétérogène de désordres métaboliques génétiques. Le déficit enzymatique résultant entraîne une.

Author: Kazrajind Zukinos
Country: Morocco
Language: English (Spanish)
Genre: Literature
Published (Last): 2 September 2017
Pages: 113
PDF File Size: 11.20 Mb
ePub File Size: 9.16 Mb
ISBN: 723-6-67791-154-8
Downloads: 38689
Price: Free* [*Free Regsitration Required]
Uploader: Akikasa

The lysosomal lyysosomales disorders LSD comprise a heterogeneous group of inborn errors of metabolism. The resulting enzymatic defect leads to accumulation of its substrate in the lysosome. Their clinical patterns reflect the site of substrate storage. Central nervous system involvement is often present in the younger patients affected by the most severe phenotypes.

ERA-Net E-Rare | ERA-Net for Research Programmes on Rare Diseases

Substantial progress has been made in the pathophysiological knowledge, leading to new therapeutic options in LSD. This treatment reduces lysosomal storage, and sometimes oysosomales, but most often limits the progression of visceral involvement and of its clinical consequences.


However, ERT does not cross the blood-brain barrier and is ineffective on neurological symptoms. In the younger patients with MPS I Hurler disease and with selected cases of other LSD, haematopoietic stem cell transplantation remains the optimal option.

Other strategies using small molecules are being explored in order lea cross the blood-brain barrier.

Vaincre les maladies lysosomales

This includes substrate reduction or depletion therapies, which decrease the amount of substrate, and the use of pharmacological chaperones, which enhance the residual activity of the lysosomale enzyme. Miglustat is the proposed substrate reduction therapy in Niemann-Pick C disease and clinical trials are actually performed in several LSD using other substrate reduction or chaperone drugs.

Journal page Archives Contents list. Access to the text HTML. Access to the PDF text. Access to the full text of this article requires a subscription. If you are a subscriber, please sign in ‘My Account’ at the top right of the screen. If you want to subscribe to this lysosomale, see our rates You can purchase this item in Pay Per View: Outline Masquer le plan. Top malavies the page – Article Outline.



Contact Lysosomalles Who are we? As per the Law relating to information storage and personal integrity, you have the right to oppose art 26 of that lawaccess art 34 of that law and rectify art 36 of that law your personal data.

You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted. Personal information regarding our website’s visitors, including their identity, is confidential.

The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties. You can maladiea this window by clicking on the headline.